Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Amgen, Inc.    AMGN   US0311621009

AMGEN, INC. (AMGN)

116
Delayed Quote. Delayed Nasdaq - 07/28 02:13:52 pm
122.68 USD   -0.13%
10h ago AMGEN : Announces Webcast of 2014 Second Quarter Financial Results
1d ago AMGEN : Reports AMG 416 Phase 3 Results
3d ago AMGEN : Announces 2014 Third Quarter Dividend
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

04/24/2012 | 04:40pm US/Eastern
Recommend:
0

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Recommend :
0
React to this article
Latest news on AMGEN, INC.
10h ago AMGEN : Announces Webcast of 2014 Second Quarter Financial Results
1d ago AMGEN : Reports AMG 416 Phase 3 Results
3d ago AMGEN : Announces 2014 Third Quarter Dividend
3d agoDJBAYER : and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment Failed
3d ago AMGEN : Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® ..
4d ago AMGEN : Announces Webcast of 2014 Second Quarter Financial Results
6d ago CBS TECHNOLOGY BERHAD : CBSA Recognizes Amgen Foundation's $25,000 Investment in..
6d ago AMGEN : Posts AMG 416 Phase 3 Results
07/18 Strides arcolab invests in oncobiologics inc
07/17 AMGEN : Announces Positive Phase 3 Results for AMG 416 for the Treatment of Seco..
Advertisement
Chart
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Income Statement Evolution
Amgen, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF